Bharat Parenter. — Q2 FY26 earnings call

Call held 12 Nov 2025

Management summary

Bharat Parenterals Limited reported a challenging Q2 FY26 with standalone revenue declining to ₹41.7 crores due to a planned production break for upgrades, temporary softness in institutional offtake, and deferred export dispatches. Despite lower volumes, gross margins improved significantly to 44.1% (standalone) and 58.3% (consolidated) due to a shift towards higher-value products. The quarter was marked by a significant milestone for its subsidiary Innoxel Lifesciences, which received US FDA EIR, paving the way for commercial supplies to the US and EU markets. The company maintains its FY26 guidance for strong H2 recovery and profitability.

Highlights

  • Standalone revenue from operations stood at ₹41.7 crores, a 35.3% decline YoY and 55.8% QoQ.

  • Consolidated revenue was ₹64.6 crores, a 10% decline YoY and 44% sequentially.

  • Standalone gross margins expanded sharply to 44.1%, up from 33.5% last year and 33.4% in Q1.

  • Consolidated gross profit rose 26% YoY to ₹37.7 crores, with margins expanding to 58.3% from 41.8%.

  • Standalone EBITDA was ₹2.3 crores (5.6% margin), and PAT was ₹2.7 crores (6.5% margin).

  • Consolidated EBITDA turned positive at ₹80 lakhs, compared to a loss of ₹7.7 crores in Q2 FY25.

  • Innoxel Lifesciences received US FDA Establishment Inspection Report (EIR) on July 30, 2025.

  • Innoxel finalized 7 new strategic partnerships (6 EMO, 1 out-licensing) valued at $1.85 million in licensing and milestone income.

  • Varenyam Healthcare is on track to deliver ₹60-65 crores in FY26 revenue, a 20-21% growth YoY, and expects 10% PAT.

Concerns

  • Production break impact on Q2 revenue

Key financials

  1. Standalone Revenue ₹41.7 Cr -35.3%YoY
  2. Consolidated Revenue ₹64.6 Cr -10%YoY
  3. Standalone Gross Margin 44.1%
  4. Consolidated Gross Margin 58.3%
  5. Standalone EBITDA ₹2.3 Cr
  6. Standalone EBITDA Margin 5.6%
  7. Standalone PAT ₹2.7 Cr
  8. Standalone PAT Margin 6.5%
  9. Consolidated EBITDA ₹0.8 Cr
  10. Consolidated Net Loss ₹8.6 Cr

What they filed

Q1 FY27: revenue down 19.2%, net profit down 309.2% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue72 72 104 116 65 −10%65 −10%100 −4%94 −19%
EBITDA-8 4 2 14 1 +111%2 −52%-1 −123%9 −38%
Net profit-18 -8 -9 -1 -9 +51%-10 −23%-8 +14%-4 −309%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Innoxel Lifesciences
    1.85 Mn Strategic Partnerships Value₹14 Cr Quarterly Costs₹16 Cr Quarterly Costs (Upper Range)
  • Varenyam Healthcare
    ₹60 Cr FY26 Revenue Target₹65 Cr FY26 Revenue Target (Upper Range)20% FY26 Revenue Growth10% FY26 PAT Margin Target45% Anesthesia Division H1 FY26 Margin39% Anesthesia Division Last Year Margin

Order book

high confidence

Total value

₹210 Cr

as of 2024-09-30 quantified

Execution

First tranche completed in Q1 FY26, second and third in H2 FY26, last tranche in Q1 FY27.

The company has a robust order book for its standalone business, with a significant institutional order being executed in tranches.

Source: Q&A

Capital allocation

high confidence
  • Capex ₹120 Cr through internal accruals at BPL
    • Varenyam Bio plant construction (general block completed, oncology block starting) ₹35 Cr
    • Varenyam Bio plant construction (general block completed, oncology block starting) ₹40 Cr
    So, Varenyam Bio was the total CapEx outlay is around Rs. 120 crores, which is expected for the entirety of the plant. As of now, the general block is completely constructed. We are beginning the second phase of our construction, which would be the oncology block as we speak. Around Rs. 35 crores to Rs. 40 crores of investment has already been completed through internal accruals at BPL.
  • Debt Debt disclosed
    the debt levels have gone down on a standalone basis.
  • M&A 7 new strategic partnerships (6 EMO contracts, 1 out-licensing deal) Acquisition · Signed · Consideration ₹[object Object] (undisclosed)

    Expand pipeline and market reach for Innoxel Lifesciences

    Valued at $1.85 million in licensing and milestone income for Innoxel.

    During the quarter, Innoxel finalized 7 new strategic partnerships including 6 EMO contracts and one out-licensing deal, together valued at $1.85 million in licensing and milestone income.

Guidance & targets

Revenue

  • Standalone Revenue Growth Revenue · FY26 · High confidence 12-14%
    For the standalone business, we maintain our FY '26 guidance of 12% to 14% revenue growth with EBITDA margins of 15% to 17%, supported by a robust order book and improved utilization.

    — Bhahim Desai

  • Innoxel Revenue Revenue · FY26 · High confidence ₹65-70 crores
    Innoxel is expected to deliver Rs. 65 crores to Rs. 70 crores in revenue this year, driven by milestone receipts, while commercial CMO supplies are expected to commence from Q1 of FY '27.

    — Bhahim Desai

  • Innoxel Revenue Revenue · FY27 · High confidence ₹110-135 crores
    So, FY '27 for Innoxel, the top line, obviously, depending the U.S. business and the EU business commencing from Quarter 1 of '27, we expect the top line to be anywhere between Rs. 110 crores to Rs. 130 crores, Rs. 135 crores in top line.

    — Bhahim Desai

  • Varenyam Healthcare Revenue Revenue · FY26 · High confidence ₹60-65 crores
    It remains on track to deliver Rs. 60 crores to Rs. 65 crores in FY '26 revenue, a healthy 20%-21% growth over last year.

    — Bhahim Desai

  • Varenyam Bio Revenue Revenue · next 18 to 24 months · Medium confidence Cross ₹100 crores
    Just to give you a little bit of brief on the overall aspects of Varenyam, we expect to cross the Rs. 100 crore mark in the next 18 to 24 months.

    — Bhahim Desai

  • Varenyam Bio Top Line Revenue · long-term · Medium confidence ₹250-300 crores
    And we aim to be at least a Rs. 250 crores to Rs. 300 crore top line company with three to four divisions that are in pipeline as we speak right now.

    — Bhahim Desai

  • Standalone Overall Growth Revenue · next five years · Medium confidence 10-12%
    but we expect an overall growth of 10% to 12% over the next five years on the standalone basis.

    — Bhahim Desai

  • Innoxel FY27 Milestone Revenue (Confirmed) Revenue · FY27 · High confidence ₹65 crores
    I would say around Rs. 65 crores of milestone revenue is confirmed for FY '27 from the Rs. 120 crores, Rs. 130-odd crores of top line revenue that we are targeting.

    — Bhahim Desai

Margin

  • Standalone EBITDA Margin Margin · FY26 · High confidence 15-17%
    For the standalone business, we maintain our FY '26 guidance of 12% to 14% revenue growth with EBITDA margins of 15% to 17%, supported by a robust order book and improved utilization.

    — Bhahim Desai

Profitability

  • Innoxel EBITDA Profitability · FY26 · High confidence Breakeven
    Innoxel also stands to be breaking even on EBITDA levels this year.

    — Bhahim Desai

  • Innoxel EBITDA Profitability · FY27 · High confidence ₹35-50 crores
    And EBITDA would be anywhere between Rs. 35 crores to Rs. 50 crores for next fiscal year.

    — Bhahim Desai

  • Varenyam Healthcare PAT Margin Profitability · FY26 · High confidence 10%
    This year, we are in line to have a 10% PAT on the top line of Varenyam.

    — Bhahim Desai

Capacity

  • Varenyam Bio Operational Status Capacity · FY26 end · High confidence Completely operational
    We expect to be completely operational by FY '26 end and the regulatory phase to start by early '27.

    — Bhahim Desai

Regulatory

  • Varenyam Bio Regulatory Phase Start Regulatory · early FY27 · High confidence Early FY27
    We expect to be completely operational by FY '26 end and the regulatory phase to start by early '27.

    — Bhahim Desai

  • Innoxel EU GMP Inspection Regulatory · second half of this fiscal · High confidence Expected
    An EU GMP inspection is expected in second half of this fiscal, with four commercial filings targeted in Q1 of FY '27.

    — Bhahim Desai

  • Innoxel Commercial Filings Regulatory · Q1 FY27 · High confidence 4 filings

    — Bhahim Desai

Costs

  • Innoxel Quarterly Costs Costs · per quarter · High confidence ₹14-16 crores
    Quarterly costs remain stable between Rs. 14 crores and Rs. 16 crores per quarter, and the business is well on track towards operational breakeven in FY '26.

    — Bhahim Desai

Product Pipeline

  • Innoxel Active Products Product Pipeline · current · High confidence Around 20
    Its pipeline now includes around 20 active products, both which are 505(b)(2) NDAs, complex AND As, and also including long-acting as well as liposome-based injectables, with more than 40 molecules under lifetime development.

    — Bhahim Desai

  • Innoxel Molecules under Lifetime Development Product Pipeline · lifetime · High confidence More than 40

    — Bhahim Desai

  • Innoxel Products under own banner Product Pipeline · lifetime of organization · High confidence 40 products
    But what has now been outlined by the management is that in the lifetime of the organization, we would be having around 40 products and we would maintain that 40 products under our own banner.

    — Bhahim Desai

Market context

  • Consolidated PAT Profitability · FY27 · High confidence Positive
    At a consolidated level, we expect FY '26 with a clear path towards positive PAT by '27, supported by recovery in standalone operations and sustained progress at Innoxel.

    — Bhahim Desai

What to watch in Q3 FY26

Standalone Revenue Growth

H2 FY26
Current -35.3% YoY, -55.8% QoQ
Target Recovery to 12-14% YoY growth for FY26

Why it matters

Verifies the effectiveness of strategic upgrades and normalization of institutional orders, crucial for overall FY26 guidance.

We expect momentum to recover strongly in H2 of FY '26 as capacity utilization improves and institutional orders normalize.

Risks & concerns

  • Production break impact on Q2 revenue

    high

    Planned near one-month production break to upgrade general injectables line to higher ORAP standards led to revenue decline.

    Management acknowledged

  • Temporary softness in institutional offtake

    medium

    Followed an exceptionally strong Q1, contributing to Q2 revenue decline.

    Management acknowledged

  • Deferred export dispatches

    medium

    Contributed to Q2 revenue decline, but expected to roll into Q3.

    Management acknowledged

  • Increased competition in ROW markets

    medium

    Due to other manufacturers shifting to ROW markets following global tariff changes, company plans to enter newer, more stringent regulatory markets.

    Analyst acknowledged

  • Delay in EU GMP inspection

    low

    Confirmed dates for May were cancelled due to India-Pakistan war and travel advisory; new inspections expected shortly from Belgian authorities.

    Management acknowledged

Q&A highlights

7 direct
Innoxel FY27 Topline and EBITDA Margins Direct
So, FY '27 for Innoxel, the top line, obviously, depending the U.S. business and the EU business commencing from Quarter 1 of '27, we expect the top line to be anywhere between Rs. 110 crores to Rs. 130 crores, Rs. 135 crores in top line. And EBITDA would be anywhere between Rs. 35 crores to Rs. 50 crores for next fiscal year.

Provides specific financial targets for the key subsidiary's future performance, crucial for valuation.

Asked by Bajrang Bafna

Impact of Q2 Upgradation on Standalone Revenue Direct
We would have been somewhere positive of last year's number. So, we could have expected somewhere around Rs. 60 crores to Rs. 65 crores of revenue on the standalone basis.

Quantifies the revenue loss due to the planned production break, helping investors understand the underlying business health.

Asked by Anupam Agarwal

Nature and Purpose of Q2 Upgradation Direct
This was part of strategic long-term planning. We upgraded our lines to an ORABS line... That was done for our upcoming audits at the BPL facility. We are expecting two major audits in the next year. One would be EU GMP audits of our newly built Beta-Lactam block. And the second would be PIC/S audit for our general block.

Explains the strategic rationale behind the production break, linking it to future regulatory compliance and market access.

Asked by Anupam Agarwal

Varenyam Healthcare Business Model and Margins Direct
So, Varenyam Healthcare is a branded domestic generics business... It is currently a single division organization with more divisions lined up in the next 18 months... we are into anesthesia, critical care, and pain management side of the IPM... we have successfully been able to expand our margin profiles from 39% last year to 45% this year until the H1.

Provides detailed insight into the operations, market positioning, and improving profitability of a key domestic segment.

Asked by Dhruvesh Sanghvi

Competition in ROW Markets due to Global Tariff Changes Partial
Now, as things stand, generics, any and all types of generics are completely exempted towards any type of tariffs... While the other aspect what you asked is that because of this, the natural tendency of other manufacturers would be to shift to other markets. So, definitely we are also, on a standalone basis, working to ensure that while the competition may increase in the other ROW markets, we should be well-poised to enter newer markets where, again, there is a more stringent regulatory check required.

Addresses a potential industry-wide risk and outlines the company's strategy to mitigate increased competition in certain markets.

Asked by Dhruvesh Sanghvi

Varenyam Bio CapEx Status and Timeline Direct
So, Varenyam Bio was the total CapEx outlay is around Rs. 120 crores... Around Rs. 35 crores to Rs. 40 crores of investment has already been completed... We expect to be completely operational by FY '26 end and the regulatory phase to start by early '27.

Clarifies the progress and timeline for a significant growth project, including its financial outlay and operational readiness.

Asked by Dhruvesh Sanghvi

Innoxel FY27 Milestone vs Commercial Revenue Mix Direct
I would say around Rs. 65 crores of milestone revenue is confirmed for FY '27 from the Rs. 120 crores, Rs. 130-odd crores of top line revenue that we are targeting. Rest would be from our commercial supplies that are poised to start from Q1 of '27.

Provides a crucial breakdown of Innoxel's projected FY27 revenue, distinguishing between one-time milestones and recurring commercial supplies.

Asked by Anupam Agarwal

Delay in Innoxel EU GMP Approval vs US FDA Direct
No, so we had confirmed dates for May. It was the same week that India-Pakistan war happened. Because of the travel advisory, we had a confirmed inspection from Portugal. And because of that, there was a trial advisory and those inspections got cancelled for those dates... Since we were already in touch with the Belgian authorities as well, the Belgian authorities confirmed earlier on and now the new inspections are going to happen shortly from the Belgian authorities.

Explains the specific, external reason for the delay in EU GMP inspection, reassuring investors that it wasn't due to internal issues.

Asked by Dhruvesh Sanghvi

2 min read 5 chapters

Detailed narrative

Q2 FY26 Performance Overview

Standalone revenue from operations for Q2 FY26 was ₹41.7 crores, a significant decline from ₹64.5 crores in Q2 FY25 and ₹94.4 crores in Q1 FY26. This decline was anticipated due to a planned one-month production break for facility upgrades, temporary softness in institutional offtake, and deferred export dispatches. Despite lower volumes, standalone gross margins expanded sharply to 44.1% from 33.5% last year, reflecting a shift towards higher-value products and improved efficiency. Standalone EBITDA stood at ₹2.3 crores (5.6% margin) and PAT at ₹2.7 crores (6.5% margin), demonstrating continued profitability.

Consolidated Performance and Margin Expansion

On a consolidated basis, revenue for Q2 FY26 was ₹64.6 crores, representing a 10% year-on-year decline and a 44% sequential drop. However, the underlying performance showed significant strengthening, with consolidated gross profit rising 26% year-on-year to ₹37.7 crores. Consolidated gross margins expanded notably to 58.3% from 41.8% in the previous year, primarily driven by a favorable product mix and procurement discipline. Consolidated EBITDA turned positive at ₹80 lakhs, a substantial improvement from a loss of ₹7.7 crores in Q2 FY25, and net loss nearly halved to ₹8.6 crores.

Innoxel Lifesciences: US FDA EIR and Strategic Partnerships

Innoxel Lifesciences achieved a major milestone by receiving the US FDA Establishment Inspection Report (EIR) on July 30, 2025, confirming its approved status for the Vadodara manufacturing facility. This approval is transformational, enabling commercial supplies to the US and EU markets. During the quarter, Innoxel also finalized seven new strategic partnerships, including six EMO contracts and one out-licensing deal, collectively valued at $1.85 million in licensing and milestone income. The subsidiary's pipeline now includes approximately 20 active products, with over 40 molecules under lifetime development, and it expects an EU GMP inspection in H2 FY26.

Varenyam Healthcare: Domestic Growth and Profitability

Varenyam Healthcare, the domestic formulations arm, continues its strong performance, focusing on critical care and anesthesia segments. The division is on track to achieve ₹60-65 crores in revenue for FY26, representing a healthy 20-21% year-on-year growth. It is also expected to deliver a 10% PAT margin on its top line for the year. The anesthesia division, a core competency, has seen its margins expand from 39% last year to 45% in H1 FY26, with management aiming to maintain these levels in H2.

Strategic Upgrades and Future Outlook

The company undertook significant infrastructural upgrades, including the conversion of its general injectables line to higher ORABS standards and improvements to purified water systems in the Beta-Lactam Block. These upgrades were part of a strategic long-term plan to ensure compliance with stringent regulatory requirements for upcoming EU GMP and PIC/S audits. Management remains confident of a strong rebound in H2 FY26 for the standalone business, maintaining FY26 revenue growth guidance of 12-14% and EBITDA margins of 15-17%, supported by a robust order book and improved utilization. Innoxel is projected to achieve EBITDA breakeven in FY26 and deliver ₹110-135 crores in revenue by FY27.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls